BDHI.BO
Latest Trade
85.95INRChange
-0.75(-0.87%)Volume
2,595Today's Range
-
87.6052 Week Range
-
98.95As of on the Bombay Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 86.70 |
---|---|
Open | 84.00 |
Volume | 2,595 |
3M AVG Volume | 0.11 |
Today's High | 87.60 |
Today's Low | 83.50 |
52 Week High | 98.95 |
52 Week Low | 47.05 |
Shares Out (MIL) | 5.76 |
Market Cap (MIL) | 499.16 |
Forward P/E | -- |
Dividend (Yield %) | 2.88 |
BDH Industries Ltd - Recommended Dividend At 2.50 Rupees per Share
India's BDH Industries Dec-Qtr Profit Rises
India's BDH Industries Sept Qtr PAT Rises
BDH Industries Limited is engaged in the manufacturing of therapeutic formulations covering a range of pharmaceuticals. The Company offers a range of oral solid dosage (OSD) technologies. The Company offers its products in various therapeutic classes, such as antifungal, antibiotics, anticancer, anti-diabetic, antidepressant, anti-ulcerant, antimalarial, anti-inflammatory, analgesic, antispasmodic, anti-tuberculosis, cardiovascular, dermatological, non-steroidal anti-inflammatory drugs, psychotropic, trichology, and vitamins and minerals. Its products include formulations, such as KALPANJAN Forte Pain Balm, Oxytetracyclin Eye Ointment and Paclitaxel Injection; specialty formulations, such as Morphine Sulphate Slow Release Tablets 15mg and Sulfasalazine Delayed release tablets U.S.P. 500mg, and bulk drugs, such as ERYTHROMYCIN BASE BP 93/USP XXIII and AZITHROMYCIN DIHYDRATE USP XXIII. The Company also offers Sildenafil Citrate Tablets (SOULFIL) for men erectile dysfunction.
Industry
Biotechnology & Drugs
Contact Info
Nair Baug, Akurli Road, Kandivali (East)
400101
India
+91.22.61551234
http://www.bdhind.com/Executive Leadership
Jayashree Nair
Executive Chairperson of the Board, Managing Director
Nikita Phatak
Compliance Officer, Company Secretary
S. C. Kachhara
Executive Director
Karthika Nair
Non-Executive Director
Kairav Trivedi
Independent Director
Price To Earnings (TTM) | 8.85 |
---|---|
Price To Sales (TTM) | 0.96 |
Price To Book (MRQ) | 1.25 |
Price To Cash Flow (TTM) | 7.66 |
Total Debt To Equity (MRQ) | 16.38 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | 14.52 |
Return on Equity (TTM) | 8.64 |
* DEC QUARTER PROFIT 12 MILLION RUPEES VERSUS PROFIT 9.3 MILLION RUPEES YEAR AGO
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.